




# TIMELINE OF MEDICATION ABORTION IN THE UNITED STATES



1. Center for Drug Evaluation and Research. "Approval Letter for Mifeprex: NDA 20-687." U.S. Food and Drug Administration. 2000. Washington, DC. [https://www.accessdata.fda.gov/drugsatfda\\_docs/applletter/2000/20687apltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2000/20687apltr.pdf)

2. U.S. Food and Drug Administration. "Regulatory Information: Food and Drug Administration Amendments Act (FDAAA) of 2007." U.S. Department of Health and Human Services. 2007. Washington, DC. <https://www.fda.gov/regulatoryinformation/html>

3. U.S. Food and Drug Administration. "Initial REMS Approval: NDA 20-687." Danco Laboratories. 2011. New York, NY. <http://www.earlyoptionpill.com/wp-content/uploads/2016/02/REMS-March2016.pdf>

4. U.S. Food and Drug Administration. "Drug Safety: Mifeprex (mifepristone) Information – FDA Approved Regimen 2016." U.S. Department of Health and Human Services. 2018. Washington, DC. <https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111323.htm>

5. Grossman, Daniel, et al. "Safety of Medical Abortion Provided Through Telemedicine Compared With In Person." American Journal of Obstetrics and Gynecology. 2017. Washington, DC. [https://journals.lww.com/greenjournal/Fulltext/2017/10000/Safety\\_of\\_Medical\\_Abortion\\_Provided\\_Through.16.aspx](https://journals.lww.com/greenjournal/Fulltext/2017/10000/Safety_of_Medical_Abortion_Provided_Through.16.aspx)

6. U.S. Food and Drug Administration. Letter to American College of Obstetricians and Gynecologists. 2021. Silver Spring, MD. <https://www.tps://www.aclu.org/letter/fda-response-acog-april-2021>

7. ACLU. Joint Motion to Stay Case in Chelius v. Becerra. 2021. <https://www.aclu.org/legal-document/joint-motion-stay-case-pending-agency-review>